Summary:
The purpose of this study is to demonstrate that study drug 1 mg once-weekly improves clinical outcomes including walking distance compared to placebo in patients with type 2 diabetes and intermittent claudication due to peripheral arterial disease (PAD). The study requires 9 visits over the period of 1 year. The medication is a weekly injection. Subjects will be required to walk on a treadmill at a very slow pace. Subjects will be seen by a board-certified physician and the study nurse. Compenation will be provided for completed visits.
Qualified Participants Must:
• Be at least 18 years of age
• have controlled Type 2 diabetes
• have pain in the calves when walking that stops at rest
• be willing to attend study visits about once per month for the first 3 months and every three months following
• be able and willing to walk on a treadmill
• must not be taking a GLP-1 receptor antagonist such as Victoza
Qualified Participants May Receive:
All Medical evaluations, study treatment or placebo, monitoring throughout the study and compensation for time and travel